학술논문

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
Document Type
Article
Source
In The Lancet 1-7 April 2023 401(10382):1091-1102
Subject
Primary Research
Articles
Language
ISSN
0140-6736